Introduction
We actively develop cell therapies for various indications, aiming to provide more treatment options for patients worldwide and satisfy the unmet medical needs.
GXHPC1®, applied for the treatment of liver cirrhosis, has been demonstrated in preclinical studies to reduce liver fibrosis by 63%, promote hepatocyte regeneration, and improve liver function. This research achievement has also been granted multiple international patents.
In the Phase I clinical trial of GXHPC1®, no suspected unexpected serious adverse reactions (SUSARs) related to GXHPC1® were observed in subjects receiving treatment. Moreover, improvements were observed in liver function, METAVIR score, Child-Pugh score, MELD score, and quality of life. These results demonstrate that GXHPC1® is safe and has therapeutic potential for the treatment of liver cirrhosis.
Features / strengths
．Novel technology & product (first-in-class medicine)
．Autologous ADSCs
．Intrahepatic (IH) injection
．The outcomes of clinical trial Phase I data have been published. (Cell Transplant. 2019;28(1_suppl):100S-111S. doi:10.1177/0963689719884885)
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Indication
Liver cirrhosis
Administration
Intrahepatic injection
Product Status
Phase II (NCT04088058)
Supporting document
